[go: up one dir, main page]

GB202101299D0 - Diagnostic polypetides and methods - Google Patents

Diagnostic polypetides and methods

Info

Publication number
GB202101299D0
GB202101299D0 GBGB2101299.2A GB202101299A GB202101299D0 GB 202101299 D0 GB202101299 D0 GB 202101299D0 GB 202101299 A GB202101299 A GB 202101299A GB 202101299 D0 GB202101299 D0 GB 202101299D0
Authority
GB
United Kingdom
Prior art keywords
polypetides
diagnostic
methods
diagnostic polypetides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2101299.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avacta Life Sciences Ltd
Original Assignee
Avacta Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2008694.8A external-priority patent/GB202008694D0/en
Priority claimed from GBGB2014725.2A external-priority patent/GB202014725D0/en
Application filed by Avacta Life Sciences Ltd filed Critical Avacta Life Sciences Ltd
Priority to GBGB2103142.2A priority Critical patent/GB202103142D0/en
Publication of GB202101299D0 publication Critical patent/GB202101299D0/en
Priority to PCT/EP2021/064289 priority patent/WO2021249786A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB2101299.2A 2020-06-09 2021-01-29 Diagnostic polypetides and methods Ceased GB202101299D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2103142.2A GB202103142D0 (en) 2020-06-09 2021-03-05 Diagnostic polypeptides and methods
PCT/EP2021/064289 WO2021249786A1 (en) 2020-06-09 2021-05-27 Sars-cov2 diagnostic polypeptides and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2008694.8A GB202008694D0 (en) 2020-06-09 2020-06-09 Pathogen binding polypeptides, and uses related thereto
GBGB2014725.2A GB202014725D0 (en) 2020-09-18 2020-09-18 Diagnostic polypeptides and methods

Publications (1)

Publication Number Publication Date
GB202101299D0 true GB202101299D0 (en) 2021-03-17

Family

ID=74865382

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2101299.2A Ceased GB202101299D0 (en) 2020-06-09 2021-01-29 Diagnostic polypetides and methods
GBGB2103142.2A Ceased GB202103142D0 (en) 2020-06-09 2021-03-05 Diagnostic polypeptides and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB2103142.2A Ceased GB202103142D0 (en) 2020-06-09 2021-03-05 Diagnostic polypeptides and methods

Country Status (2)

Country Link
GB (2) GB202101299D0 (en)
WO (1) WO2021249786A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121013863A (en) * 2023-03-31 2025-11-25 艾菲赛尔治疗株式会社 TNFR2-binding peptides and their usage
FR3147278A1 (en) * 2023-03-31 2024-10-04 Avacta Life Sciences Limited TNFR2-BINDING POLYPEPTIDES AND METHODS OF USE
GB202403780D0 (en) * 2024-03-15 2024-05-01 Avacta Life Sciences Ltd Polypeptides and methods for detecting and quantifying small molecules

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216034A (en) 1879-06-03 Improvement in weather-strips for doors
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB1329791A (en) 1971-01-19 1973-09-12 Niro Atomizer As Spray drying devices for the production of powder eg milk powder
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
ATE12348T1 (en) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr PROCESS FOR THE PRODUCTION OF LIPID VESICLES BY ULTRASONIC TREATMENT, APPLICATION OF THE PROCESS AND DEVICE FOR CARRYING OUT THE PROCESS.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Pharmaceutical compositions for tumour treatment
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (en) 1983-09-26 1997-11-15 Ehrenfeld Udo AGENT AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES OF THE CELLULAR AND HUMORAL IMMUNE DEFENSE
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5175154A (en) 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
JP2914692B2 (en) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ Endothelial cell genetic modification
JPH04507041A (en) 1988-12-13 1992-12-10 アメリカ合衆国 Endothelial cells modified by genetic engineering and methods for their use
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
KR920007887B1 (en) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 Exhaust gas cleaning device for internal combustion engine
US5360478A (en) 1989-10-16 1994-11-01 Phasex Corporation Gas anti-solvent recrystallization process
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
EP0572401B2 (en) 1991-02-19 2007-11-07 The Regents of the University of California Viral particles having altered host range
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5389263A (en) 1992-05-20 1995-02-14 Phasex Corporation Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
FR2702160B1 (en) 1993-03-02 1995-06-02 Biovecteurs As Synthetic particulate vectors and method of preparation.
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
FR2704145B1 (en) 1993-04-21 1995-07-21 Pasteur Institut Particulate vector and pharmaceutical composition containing it.
US5407606A (en) 1994-01-10 1995-04-18 Tennessee Valley Authority Oriented spray-assisted cooling tower
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
FR2723849B1 (en) 1994-08-31 1997-04-11 Biovector Therapeutics Sa PROCESS FOR INCREASING IMMUNOGENICITY, PRODUCT OBTAINED AND PHARMACEUTICAL COMPOSITION
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US5736537A (en) 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
CA2263796A1 (en) 1996-08-16 1998-02-26 Medical Research Council Self-replicating episomal expression vectors conferring tissue-specific gene expression
EP0955999B1 (en) 1996-08-19 2001-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Novel liposome complexes for increased systemic delivery
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
GB2330907A (en) 1997-10-28 1999-05-05 Applied Imaging Int Ltd A karyotyper and methods for producing karyotypes
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
EP1102608A4 (en) 1998-07-13 2008-09-17 Genetronics Inc Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
ES2601882T5 (en) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedure to monitor the activity of an immunofunctional molecule
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
AU4996300A (en) 1999-05-10 2000-11-21 Gentronics, Inc. Method of electroporation-enhanced delivery of active agents
SE516924C2 (en) 2000-07-20 2002-03-26 Mattias Lundin Holding device for tacos
US6458738B1 (en) 2000-09-22 2002-10-01 Union Carbide Chemicals & Plastics Technology Corporation Spray-drying compositions and methods of spray-drying
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
GB0108968D0 (en) 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
JP3543326B2 (en) 2001-08-30 2004-07-14 ソニー株式会社 Information processing apparatus and method, information processing system, information distribution apparatus, recording medium, and program
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
JP2006520584A (en) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． Stabilized single domain antibody
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
US7923251B2 (en) 2005-02-23 2011-04-12 The Board Of Trustees Of The Leland Stanford Junior University Method and apparatus for avalanche-mediated transfer of agents into cells
US8101169B2 (en) 2005-02-23 2012-01-24 The Board Of Trustees Of The Leland Stanford Junior University Ocular gene therapy using avalanche-mediated transfection
EP3613767A1 (en) 2005-05-18 2020-02-26 Ablynx N.V. Improved nanobodiestm against tumor cecrosis factor-alpha
ATE477272T1 (en) 2005-06-10 2010-08-15 Medical Res Council USE OF STEFIN A AS A SUPPORTING PROTEIN
US8399201B2 (en) 2005-10-31 2013-03-19 Janssen Pharmaceutica N.V. Polypeptide complex of TRPM8 and calmodulin and its uses thereof
JP2010500876A (en) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Amino acid sequence directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6 mediated signaling
JP4616237B2 (en) 2006-11-07 2011-01-19 日本電信電話株式会社 Method for forming silicon compound thin film
EP1995327A1 (en) 2007-05-21 2008-11-26 Humboldt Universität zu Berlin Probe for detecting a particular nucleic acid sequence
CN101796072B (en) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 Amino acid sequences against RANK-L and polypeptides comprising same for the treatment of bone diseases and disorders
US8399261B2 (en) 2007-06-27 2013-03-19 Inbios International, Inc. Lateral flow assay system and methods for its use
DE102007052517A1 (en) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT process with two filter systems
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
GB0807065D0 (en) 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
JP5684130B2 (en) 2008-09-26 2015-03-11 トカジェン インコーポレーテッド Recombinant vector
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
JP5923037B2 (en) 2009-06-17 2016-05-24 トカジェン インコーポレーテッド Production cell of replicable retroviral vector
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2911736A4 (en) 2012-10-25 2016-06-15 Oncosec Medical Inc Electroporation device
EP3623478A1 (en) 2012-10-25 2020-03-18 Tocagen Inc. Retroviral vector with mini-promoter cassette
GB201302597D0 (en) 2013-02-14 2013-04-03 Univ Leeds Novel Synthetic Proteins
JP2016526920A (en) 2013-08-05 2016-09-08 トカジェン インコーポレーテッド Recombinant vector with optimized A-bulge
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
ES2736127T3 (en) 2014-03-20 2019-12-26 Bristol Myers Squibb Co Type III domains of seroalbumin binding fibronectin
ES2779149T3 (en) 2014-03-26 2020-08-13 Tocagen Inc Retroviral vector that has immunostimulatory activity
WO2015196118A1 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
EP3157573A4 (en) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US20170175129A1 (en) 2014-06-19 2017-06-22 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
AU2015289583A1 (en) 2014-07-16 2017-02-02 Modernatx, Inc. Chimeric polynucleotides
EP3799879B1 (en) 2015-01-09 2025-06-04 Grand Decade Developments Limited Gene therapy using co-stimulatory molecule and cytokine for the treatment of malignancies
EP3247363A4 (en) 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016118725A1 (en) 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2016154473A1 (en) 2015-03-26 2016-09-29 Oncosec Medical Incorporated Method for the treatment of malignancies
DK3277368T3 (en) 2015-03-31 2020-07-27 Oncosec Medical Inc SYSTEMS FOR IMPROVED TISSUE REGISTRATION-BASED ELECTROPORATION
US10808242B2 (en) 2015-08-28 2020-10-20 Biontech Rna Pharmaceuticals Gmbh Method for reducing immunogenicity of RNA
WO2017040815A1 (en) 2015-09-04 2017-03-09 Tocagen Inc. Recombinant vectors comprising 2a peptide
AU2016324463B2 (en) 2015-09-17 2022-10-27 Modernatx, Inc. Polynucleotides containing a stabilizing tail region
CN108290941A (en) 2015-09-23 2018-07-17 百时美施贵宝公司 The seralbumin associativity fibronectin type III domain of fast dissociation rate
CN109642240A (en) 2015-12-18 2019-04-16 昂科赛克医疗公司 The plasmid construction and application method of heterologous protein expression
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins

Also Published As

Publication number Publication date
GB202103142D0 (en) 2021-04-21
WO2021249786A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
GB202101299D0 (en) Diagnostic polypetides and methods
GB2591554B (en) Composiitons and methods and uses relating thereto
IL286492A (en) Sialidase-resistant saccharide and method of making and using the same
EP3244190A4 (en) Fixture for biological tissue and method for attaching same
GB201807410D0 (en) Diagnostic method and therapy
GB202409387D0 (en) Wingsail and method
GB202007928D0 (en) New uses and methods
GB2611187B (en) Use and method
GB2614585B (en) Wingsail and method
GB2613687B (en) Aquaculture system and method
EP4419230A4 (en) Depth filters and related methods
GB202211784D0 (en) Methods and uses
GB202106040D0 (en) Methods and uses
GB202103872D0 (en) Uses and methods
GB202019660D0 (en) Uses and methods
GB2596911B (en) Method and specimen
IL275186A (en) Human anti-grp94 antibodies and uses
EP3703560A4 (en) Living body detection method and apparatus
GB202115324D0 (en) Uses and methods
GB202115327D0 (en) Uses and methods
GB202104348D0 (en) Uses and methods
GB202005589D0 (en) Medical methods and medical uses
GB202211848D0 (en) Ssensors and methods
GB202300520D0 (en) Methods and uses
GB202203804D0 (en) Uses and methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)